Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs ...

New study reveals how Atogepant prevents migraines and reduces rebound headaches in chronic sufferers, offering hope for ...

Anti-CGRP antibodies vs onabotulinumtoxinA is not associated with increased cardiovascular disease risk in older patients ...

The drug would only be available in secondary care settings at first, rather than from GPs The first oral treatment for preventing both chronic and episodic migraines could soon be available on ...